Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer and other hormonally driven cancers, today announced that updated results from its ongoing ARMOR2 Phase 2 study of its lead drug candidate, galeterone (TOK-001), in patients with castration-resistant prostate cancer (CRPC) will be presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Help employers find you! Check out all the jobs and post your resume.
